Community Update Biohaven: RESILIENT Letter to SMA Community
Biohaven released the results from their RESILIENT SMA clinical trial, and they did not meet the primary endpoint. Biohaven is currently analysing the data further and is engaging in discussion with Health Authorities.
In the meantime, taldefgrobep (the study drug) will continue to be provided to the study participants.